PET-CT Predicting Lymph Nodes Metastasis

March 19, 2026 updated by: Haiquan Chen, Fudan University

The Value of PET-CT in Predicting Lymph Nodes Metastasis in Non Small Cell Lung Cancer

This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

280

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Shanghai, China
        • Shanghai Cancer center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients had non small cell lung cancer who received pathological examination of lymph nodes

Description

Inclusion Criteria:

  • Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.
  • Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
  • Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
  • No prior radiotherapy or chemotherapy for initial treatment.
  • No history of malignant tumors.

Exclusion Criteria:

  • Locally advanced or distant metastasis.
  • Pleural dissemination observed during surgery.
  • History of malignant tumors.
  • Received neoadjuvant therapy.
  • Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Predictive value of 18F-FDG-PET/CT and 18F-FAPI-PET/CT for lymph node metastasis
Time Frame: from enrollment to 1 month after surgery
from enrollment to 1 month after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fudan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2023

Primary Completion (Estimated)

March 28, 2026

Study Completion (Estimated)

March 28, 2026

Study Registration Dates

First Submitted

July 23, 2023

First Submitted That Met QC Criteria

July 23, 2023

First Posted (Actual)

August 1, 2023

Study Record Updates

Last Update Posted (Actual)

March 23, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ECTOP-1017

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non Small Cell Lung Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe